Cite
HARVARD Citation
Zhou, J. et al. (2022). Liver Immune-related Adverse Effects of Programmed Cell Death 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Inhibitors: A Propensity Score Matched Study with Competing Risk Analyses. Clinical oncology. 34 (7), pp. e316-e317. [Online].